Use of microvesicles (MVS) for preparing a medicament having adjuvant activity on endothelial cell transplantation, particularlly in the treatment of diabetes by pancreatic islet transplantation, and related method

Vincenzo CANTALUPPI; CHIARA DEREGIBUS MARIA; CAMUSSI GIOVANNI

Use of microvesicles (MVS) for preparing a medicament having adjuvant activity on endothelial cell transplantation, particularlly in the treatment of diabetes by pancreatic islet transplantation, and related method

Vincenzo CANTALUPPI (Inventor)
, CHIARA DEREGIBUS MARIA (Inventor)
, CAMUSSI GIOVANNI (Inventor)

Department of Translational Medicine

Research output: Patent

Abstract

The invention relates to the use of microvesicles derived from cells of the endothelial cell lineage, preferably from endothelial progenitor cells, as an adjuvant agent in endothelial cell-pancreatic islet transplantation, particularly in the treatment of type I or type II diabetes by pancreatic islet transplantation. The adjuvant effect of the microvesicles consists in the improvement of survival and functionality of the transplanted islets. The adjuvant effect of the microvesicles is maintained even when the recipient is subjected to rapamycin-based immunosuppression.

Original language	English
Patent number	WO2009050742 (A1)
Publication status	Published - 1 Jan 2007

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

http://hdl.handle.net/11579/71805

Fingerprint

Dive into the research topics of 'Use of microvesicles (MVS) for preparing a medicament having adjuvant activity on endothelial cell transplantation, particularlly in the treatment of diabetes by pancreatic islet transplantation, and related method'. Together they form a unique fingerprint.

Cite this

@misc{97545782d7ea4ddbbfcc9db8a5fb3d49,

title = "Use of microvesicles (MVS) for preparing a medicament having adjuvant activity on endothelial cell transplantation, particularlly in the treatment of diabetes by pancreatic islet transplantation, and related method",

abstract = "The invention relates to the use of microvesicles derived from cells of the endothelial cell lineage, preferably from endothelial progenitor cells, as an adjuvant agent in endothelial cell-pancreatic islet transplantation, particularly in the treatment of type I or type II diabetes by pancreatic islet transplantation. The adjuvant effect of the microvesicles consists in the improvement of survival and functionality of the transplanted islets. The adjuvant effect of the microvesicles is maintained even when the recipient is subjected to rapamycin-based immunosuppression.",

author = "Vincenzo CANTALUPPI and MARIA, \{CHIARA DEREGIBUS\} and CAMUSSI GIOVANNI",

year = "2007",

month = jan,

day = "1",

language = "English",

type = "Patent",

note = "WO2009050742 (A1)",

}

Use of microvesicles (MVS) for preparing a medicament having adjuvant activity on endothelial cell transplantation, particularlly in the treatment of diabetes by pancreatic islet transplantation, and related method. / CANTALUPPI, Vincenzo (Inventor); MARIA, CHIARA DEREGIBUS (Inventor); GIOVANNI, CAMUSSI (Inventor).
Patent No.: WO2009050742 (A1). Jan 01, 2007.

Research output: Patent

TY - PAT

T1 - Use of microvesicles (MVS) for preparing a medicament having adjuvant activity on endothelial cell transplantation, particularlly in the treatment of diabetes by pancreatic islet transplantation, and related method

AU - CANTALUPPI, Vincenzo

AU - MARIA, CHIARA DEREGIBUS

AU - GIOVANNI, CAMUSSI

PY - 2007/1/1

Y1 - 2007/1/1

N2 - The invention relates to the use of microvesicles derived from cells of the endothelial cell lineage, preferably from endothelial progenitor cells, as an adjuvant agent in endothelial cell-pancreatic islet transplantation, particularly in the treatment of type I or type II diabetes by pancreatic islet transplantation. The adjuvant effect of the microvesicles consists in the improvement of survival and functionality of the transplanted islets. The adjuvant effect of the microvesicles is maintained even when the recipient is subjected to rapamycin-based immunosuppression.

AB - The invention relates to the use of microvesicles derived from cells of the endothelial cell lineage, preferably from endothelial progenitor cells, as an adjuvant agent in endothelial cell-pancreatic islet transplantation, particularly in the treatment of type I or type II diabetes by pancreatic islet transplantation. The adjuvant effect of the microvesicles consists in the improvement of survival and functionality of the transplanted islets. The adjuvant effect of the microvesicles is maintained even when the recipient is subjected to rapamycin-based immunosuppression.

UR - https://iris.uniupo.it/handle/11579/71805

M3 - Patent

M1 - WO2009050742 (A1)

ER -

Use of microvesicles (MVS) for preparing a medicament having adjuvant activity on endothelial cell transplantation, particularlly in the treatment of diabetes by pancreatic islet transplantation, and related method

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this